Wednesday, January 21, 2026

Fw: Ref.: (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 129, December 2025

 

Leprosy Mailing List �C   January 21,  2026

 

Ref.:  (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 129, December 2025

From: Takahiro NANRI, Tokyo, Japan

____________________________________________________________________________

 

Dear Dr. Schreuder and Friends,  

 

Warm greetings from Sasakawa Health Foundation/ Sasakawa Leprosy (Hansen's Disease) Initiative in Tokyo.

We have issued WHO Goodwill Ambassador's Leprosy Bulletin NO.129 December 2025 "Achieving our goals with dedication and compassion." In this issue, we feature: 

 

MESSAGE FROM THE AMBASSADOR
On Nov. 28, 2025, I met with the 14th Dalai Lama for the first time in 11 years. The year before that last meeting, in 2013, we visited one of India's approximately 750 leprosy colonies together. His Holiness was moved and surprised me by offering to use his own book royalties to support young people living in the colonies to pursue higher education. Read More 

 

VIEWPOINT
Empowerment cannot exist without ownership: Members of the Drafting Committee reflect on the 3rd Global Forum's outcome documents

The 3rd Global Forum of People's Organizations on Leprosy/ Hansen's Disease, facilitated by the Sasakawa Leprosy Initiative, took place July 4�C6, 2025, in Bali, Indonesia. More than 110 representatives of organizations of persons affected by leprosy from 21 countries participated. Read more

 

VIEWPOINT
Persons affected by leprosy research stigma and discrimination in India and Brazil

Ashutosh Prabhavalkar, Head of Program (Leprosy),  ALERT-India

Francilene Carvalho de Mesquita Volunteer and Deputy Coordinator, Department of Policies for Women, MORHAN National Volunteer, MORHAN Piauí  

Read the article

 

AMBASSADOR'S JOURNAL

Goodwill Ambassador Sasakawa attends national conference in Sri Lanka

On Nov. 6 and 7, the Sri Lanka National Leprosy Conference "Join Hands to End Leprosy" was held at the Cinnamon Grand Hotel in Colombo.The conference was jointly organized by Sri Lanka's Ministry of Health, the Sasakawa Leprosy (Hansen's Disease) Initiative, and the World Health Organization. Sri Lanka's head of state and government, President Anura Kumara Dissanayake, attended. Read more

 

VIEWPOINT

Commentary on Global Leprosy Update 2024  
Dr. Venkata Ranganadha Rao Pemmaraju, Program Advisor for Medical Issues, Sasakawa Health Foundation

Leprosy still exists: the data from 188 countries published by the World Health Organization (WHO) as the Global Leprosy Update 2024 confirms it. As per the update, 172,717 new leprosy cases were reported from 133 countries. WHO listed 23 countries as global priority countries, which together accounted for 96% (165,578) of new cases detected during the year. Read more

 

OBITUARY
Chiemi Sanga passed away on September 20, 2025

Contributed by Dr. Takahiro Nanri, President, Sasakawa Leprosy (Hansen's Disease) Initiative
Chiemi Sanga joined the Sasakawa Health Foundation in 2012. She started in the General Affairs Department, and then, in 2017, she moved to the Leprosy Division, where she served as Chief Program Officer and Director for eight years.  She consistently played a central role in the Nippon Foundation�CSasakawa Health Foundation Joint Leprosy Program Office, established in 2018 to enable the Nippon Foundation Group to tackle leprosy more effectively. Read more

 

BACK ISSUES 

 

We hope that you would enjoy reading the latest Leprosy Bulletin. 

 

Takahiro NANRI, Ph.D.
President, Sasakawa Leprosy (Hansen's Disease) Initiative

*********************************************************
Sasakawa Leprosy (Hansen's Disease) Initiative
Sasakawa Health Foundation
Tel
:81-3-6229-5377, Fax:81-33-6229-5388
email: hansen@shf.or.jp

*********************************************************

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/7c6f189e-e2e3-4b81-9460-a15258601bffn%40googlegroups.com.

Wednesday, January 14, 2026

Fw: Ref.: (LML) Infolep monthly overview of new publications on leprosy. December 2025


 

 

Leprosy Mailing List –  January 14,  2026

 

Ref.:  (LML) Infolep monthly overview of new publications on leprosy. December 2025

From: Elizabeth Talatu Williams, Amsterdam, the Netherlands

____________________________________________________________________________




Dear colleagues,

As we step into a new year, we are delighted to welcome you back and, slightly behind schedule, share the December 2025 edition of the Infolep Newsletter. We hope you had a restful and refreshing holiday season, and we wish you a healthy, successful, and fulfilling year ahead.

This special edition brings together a robust collection of research, case studies, and global perspectives on leprosy and related conditions. From community empowerment initiatives in Nepal and progress toward Zero Leprosy, to epidemiological insights from Africa, Asia, and Latin America, this issue reflects the continued momentum, innovation, and commitment across the global leprosy community.

In addition, this issue features global news and upcoming events for 2026, including the International Conference on Economic Inclusion for Persons with Disabilities in Dhaka and the 51st Topics in Infection meeting in London, offering important opportunities for learning, collaboration, and advocacy in the year ahead.

Looking ahead to 2026, we remain inspired by your dedication to research, care, advocacy, and elimination efforts. We hope this edition provides valuable insights, sparks new ideas, and supports your important work in the months ahead.

Thank you for being part of the Infolep community. We look forward to another year of knowledge sharing, collaboration, and impact.

Please feel free to contact us if you would like access to full-text versions that are not available on Infolep, or if you would like our support with literature searches.

Warm wishes for a successful year ahead.
Elizabeth Talatu Williams


www.leprosy-information.org
info@infolep.org
 




 



 



Featured Research Spotlight

Fostering empowerment: Transition from self-help groups to cooperatives in leprosy-affected communities in Nepal
Shrestha D, Shrestha B, Ansari S, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2025; 19 (12): 1-22. 


Zero leprosy is within reach: eliminating leprosy in low-endemic settings demands political will
Fastenau A. The Lancet Regional Health - Southeast Asia. Elsevier BV. 2026.


Epidemiology and Clinical Characteristics of Leprosy Patients at Mankweng Hospital, Limpopo Province, South Africa
Sema-Ramashala AR, Mavhungu R, Lekoloana MA. FHS Research Day 2025. MDPI. 2025. 


Leprosy in Brazil: historical trajectory, advances, and epidemiological challenges in the context of social inequalities
Costa ALP, Siqueira RL, dos Santos VDS, et al. Health Sciences - 3° Edição. Seven Editora. 2025. 


Strengthening leprosy control through capacity building of allied health workers: A pre–post design
Mohan R, Mary JJF, Balaji R, et al. Journal of Family Medicine and Primary Care. Ovid Technologies (Wolters Kluwer Health). 2025; 14 (11): 4738-4743. 


Toward Indonesia's Zero Leprosy 2030: Key Lessons from Epidemiological Trends in Papua 2020 - 2024
Sumolang I, Romadhon D, Suyanto A. Folia Medica Indonesiana. 2025; 61 (1): 128-138.


Temporal trends and identification of risk areas related to the burden of leprosy in Brazil: an ecological study from 2001 to 2021
Da Paz WS, dos Reis ES, Bezerra-Santos M, et al. Clinical and Experimental Dermatology. Oxford University Press (OUP). 2025.


Analysis of the Spatial Distribution of New Cases of Leprosy in the State of Pernambuco, Northeast Brazil
Barbosa CC, Bezerra GSN, Xavier AT, et al. Tropical Medicine and Infectious Disease. MDPI AG. 2025; 10 (12): 1-18.


Therapeutic failure of multidrug therapy for leprosy: A retrospective case series in a hyperendemic Brazilian City
Fonseca AMFDA, Rosa PS, Belone ADFF, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2025; 19 (11): 1-20.


Co-developing strategies for leprosy management in Malaysia: A transdisciplinary research approach involving individuals affected by leprosy and other stakeholders
Abdul Rahman N, Rajaratnam V, Peters RM, et al. Global Public Health. Informa UK Limited. 2025; 20 (1): 1-17.


Participatory construction of an assistive technology for leprosy contact surveillance
Duarte BAS, Nogueira LMV, Jesus HGD, et al. Revista Brasileira de Enfermagem. FapUNIFESP (SciELO). 2025; 78 (suppl 4): 1-9.

 



 



 



Other New publications


Feel free to contact us to receive full-text versions if these cannot be found through the Infolep portal.

 



Assessment of quality of life of patients with leprosy treated at a tertiary care centre in western Maharashtra
Ray AK, Tripathi S, Ali HHA, et al. International Journal Of Community Medicine And Public Health. Medip Academy. 2025; 12 (12): 5640-5644. 


Associated Factors of Mycobacterium Leprae Infection among People with Leprosy in Kwale County
Karani V, Dierro L, Rono A, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2025; 19 (11): 1-13.


Factors associated with non-adherence to polychemotherapy treatment for leprosy.
Johnne da Cruz, Eliane Franchi. Revista brasileira de enfermagem. 2025; 78 (4): 1-10.


Expanding the Genetic Insights Into Leprosy: An Updated Meta-Analysis of Interleukin-10 Variants.
Veeraraghavan J, Stephen S, Narasimhan M, et al. International journal of immunogenetics. 2025.


Self-assessment of risk of dysphagia and clinical-functional vulnerability in older adults with a history of leprosy
Rocha MC, Mourão AM, Jesus JDSD, et al. CoDAS. FapUNIFESP (SciELO). 2025; 37 (6): 1-8. 


Transmission Patterns and Factors Influencing High Incidence of Leprosy among Indigenous Penan in Sarawak, Malaysia
Maurice Steve Utap, Chirk Jenn Ng, Yew Kong Lee, et al. Journal of Community Health. 2025.


A study of correlation between anxiety and depression of leprosy patients
Dr. Rajendra Patel. International Education & Research Journal (IERJ). 2025; 11 (12): 5-7. 

 


Optimizing treatment of lepromatous form of leprosy using ofloxacin on top of standard multi-drug therapy in National Referral Hospital, Jakarta, Indonesia.
Priyanto M, Yunifananda M, Menaldi S, et al. F1000Research. 2025.


Leprosy elimination: are we winning the fight or losing focus?
Edward M, Owoicho AW. Annals of Medicine. Informa UK Limited. 2025; 57 (1): 1-9. 


The Effect of Health Education on Leprosy-Related Stigma Among Patients and Family Contacts at Prof. Dr. I.G.N.G. Ngoerah General Hospital: A Pre- and Post-Study
Luh Putu Sustiana Kartika Sari , N. L. P Ratih Vibriyanti Karna , Luh Made Mas Rusyati . JOURNAL OF BIOMEDIKA AND HEALTH. 2025; 8 (3) : 1-2.


Assess The Lived Experiences, Overall Stigma And Quality Of Life Among People Affected With Leprosy Of Selected District East Champaran, Bihar
Ms. Pooja Kumari, Dr Priyanka Chaudhary, Mrs Babita Kumari, et al. Journal for Re Attach Therapy and Developmental Diversities. 2025; 8 (1): 181-186.


Rare multisystemic complications with delayed diagnosis in two cases of leprosy
Khallouki M, Bendaoud L, Serghini S, et al. Our Dermatology Online. Our Dermatology Online. 2025.


Molecular Viability Assay: Improving Leprosy Diagnosis beyond Current Gold Standard
Clara Imaniar, Ibnu Agus Ariyanto, Yeva Rosana. Eksakta: Berkala Ilmiah Bidang MIPA. 2025; 26 (4): 456-467.

 

 



 



 



Case Reports

A Rare Occurrence of Lepra Type II Reaction in Pure Neuritic Leprosy: A Case Report
Asfaw N, Gebrewold AM. Springer Science and Business Media LLC. 2025.


Chronic Anterior Uveitis in A Patient with Treated Leprosy: A Case Report
Azib S, Nejjar Y, Achegri Y, et al. Scholars Journal of Medical Case Reports. SASPR Edu International Pvt. Ltd. 2025; 13 (10) : 2305-2306. 


Orofacial Granulomatosis Masquerading as Borderline Tuberculoid Leprosy – A Rare Case Report
Sanchita Singha , Nitin Chaudhari , Swapna Sheth . Medical Journal of Basic and Applied Research. 2025; 5 (1): 1-3.


Borderline Lepromatous Leprosy Simulating Sarcoidosis on Histopathology: A Case Report.
Vashisht K, Sahni K, Singh A. Journal of cutaneous pathology. 2025.


A Case Report:Cutaneous Leishmaniasis Mimicking Leprosy in an Immunocompetent Young Adult: A Diagnostic and Therapeutic Challenge in the old world
Albajori R, AlHader H, ALshawa K. JAAD Case Reports. Elsevier BV. 2025.


From Nerves to Nodules: A Case-Based Review of the Progression of Pure Neuritic Leprosy to Lepromatous Leprosy With Erythema Nodosum Leprosum
Choubey S, Kar HK, Behera D. Cureus. Springer Science and Business Media LLC. 2025.


Erythema Nodosum Leprosum Triggered by Herpes Simplex Infection: A Case Report
Usamah Al-Anbagi, Abdulqadir J Nashwan, Samir Al Hyassat, et al. Cureus. Springer Science and Business Media LLC 2025.


Beyond the surface: Distinguishing leprosy from fungal mimics - A case report.
Jamani N, Ismail N, Shairah M. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia. 2025.

 



 



News & Events

 


 



First Croatian leprosy case in 32 years confirmed [Learner News]


Leprosy reported in Leon County, 36th case in Florida this year [Tallahassee Democrat]


TN health officials push for early mental health support for leprosy, tuberculosis patients [The New Indian Express]


Lepra's 'Giving Shoesday' is helping to restore dignity and hope for people affected by leprosy [Charity Today]


Youth with disabilities and leprosy must be centered in rural development, Experts stress [Dhaka Tribune]


Group tackles leprosy spread in Nasarawa communities [Punch]


Leprosy Mission Nigeria Laments 'Children With Disabilities Invisible In Nigeria's Budgets' [Sahara Reporters]


Caribbean health workers unite to accelerate leprosy elimination efforts [Pan American Health Organization]


Vadodara Health Department Launches Extensive Door-to-Door Leprosy Search Campaign [English Loktej]


Romania Confirms First Leprosy Case in Over 40 Years [Romania Journal]


Study looks at migrant-linked trans­mis­sion of lep­rosy in city [Press Reader]


Mangaluru mourns Dr Derek A. Lobo, global public-health leader and leprosy expert [News Karnataka]


Ernakulam reports 35 leprosy cases under treatment as state targets eradication by 2030 [The Times of India]
 

 


Launch Of Skin Health Camp In Anse La Raye [Observer News]


International Conference on Economic Inclusion for Persons with Disabilities
Date and Location: 18th-19th January, 2026, Dhaka, Bangladesh
The International Conference on Economic Inclusion for Persons with Disabilities will bring together academics and practitioners working on disability and economic inclusion, as well as people with disabilities and their representative organisations, policymakers, and donors.
Abstract submission deadline: 31 October 2025
Registration deadline: 4 January 2026


51st Topics in Infection
Date and Time: 30 January, 8:30AM - 6:30PM GMT
Location: Goodenough College, London House, Meckleburgh Square, London WC1N 2AB
This annual one-day meeting, is delivered as a partnership between RSTMH, Barts Health and the UK Health Security Agency. It will bring together microbiologists, infectious disease physicians, infection control personnel and biomedical and clinical scientists to hear updates on recent "hot topics" in all aspects of infectious disease. Registration is open!


2nd International Conference on Tropical Dermatology 11th to 14th March, 2026
Date and Location: 11th- 14th March, 2026, Colombo, Srilanka
The second International Conference on Tropical Dermatology (ICTD), which will be held at the Shangri-La Hotel in Colombo. This esteemed event is co-organized by the Sri Lanka College of Dermatology and Aesthetic Medicine (SLCDA) in collaboration with the Deutsche Dermatologische Gesellschaft / German Dermatological Society (DDG). 

 



 


 



 



Links

 



Info Hansen - An innovative hub for knowledge sharing about Hansen's Disease
 


ALLF - Official website of the Association des Léprologues de Langue Française
 


LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in leprosy to share ideas, information, experiences and questions
 


InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)

 


ILEP newsletter archive


GPZL newsletter subscription


WHO Goodwill Ambassador's Leprosy Bulletin


Leprosy Review


Leprosy Review Repository (1928-2001)


Fontilles Revista de Leprología


Indian Journal of Leprosy


Hansenologia Internationalis


HARP -  Hansen's Disease Antimicrobial Resistance Profiles

 




GDPR & the Infolep newsletter

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our
privacy statement and mailing list.

Infolep sends out monthly e-mails with an overview of recent publications on leprosy and related issues. The purpose of this activity is to keep subscribers up to date.

Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can
update your preferences or unsubscribe from this list at any time.

 


 



 

___________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/f2c5b7c4-0470-4947-9a0c-fc84354b41d1n%40googlegroups.com.

Sunday, January 11, 2026

Fw: Ref.: (LML) Leprosy Mailing List


 

 

Leprosy Mailing List – January 11, 2026

Ref.: (LML) Leprosy Mailing List

From:  Pieter AM Schreuder, Maastricht, the Netherlands


Dear colleagues,

 

This is a reprint of the letter we sent to you previously. Mainly for those who are new to LML, but also a reminder for the regular readers. We would like to stress the following paragraph out of this letter:

 

"We would like to appeal to our readers to take up the challenge and contribute to ongoing discussions (about leprosy) or bring new items. Once more, LML is an open forum – we welcome all contributions – accept the challenge and be open-minded!"

 

Without your active contribution a forum like LML cannot exist.

 

May we wish you all the best for coming year. Let's try to make this a better world; let's try to heal the wounded and comfort those suffering.

 

Editorial board LML

 

 

LML,  September 2022:

 

"The leprosy mailing list (LML) is an e-mail-based list for sharing information among people working in the field of leprosy worldwide (Editorial Leprosy Review 2012). The first part of this letter is to welcome the newcomers to LML. The second part of this letter is of interest to all LML readers.

 

LML was started by Salvatore Noto in February 2001 at the Centre for Training and Research in Public Health (Cefpas) in Caltanissetta, Italy; from 2005 – 2013 held at the National Leprosy Referral Centre, Department of Dermatology, at San Martino University Hospital, in Genoa, Italy; and since 2013 run by Pieter AM Schreuder, Maastricht, the Netherlands. Contact: Dr Pieter Schreuder <edit...@gmail.com>

 

LML is independent and has no financial ties to any governmental or non-governmental organization or the World Health Organization (WHO). The LML blog  (LML blog link: http://leprosymailinglist.blogspot.it/) is hosted by courtesy of AIFO, Bologna, Italy. The editorial Board consists of Sunil Deepak, Ben Naafs, Salvatore Noto and Pieter Schreuder. All information passes its editorial board before being distributed. However, opinions expressed are those of the contributors and not necessarily shared by the editorial board.

 

LML accepts all contributions as long as they are relevant to leprosy. For a good understanding: LML contributions are not considered publications as a publication in a recognised recognized scientific journal. They can (and are) however be cited because represent representing professional opinions.

 

A good example of the impartiality of LML was the discussion about 'elimination.'

Although the feelings about 'elimination' on both sides of the battle ground run high, and this issue absorbed many people in the field, there did and does not exists exist a stated LML opinion. However, LML editors can on personal title contribute to the discussion as long as it is clear that they do not claim to express an "official" LML opinion.

 

LML is an open forum which that brings you in contact with almost 600 persons engaged in leprosy related leprosy-related work (from scientists to leprosy field workers, government officials to non-governmental organisations} in more than 50 countries. We like to hear the voices of all LML subscribers. Although not many people contribute actively to the discussions, many LML readers appreciate our efforts to show different opinions as was the case with the "elimination" discussion.

 

Over the past few years, we have seen a kind of turn-around in leprosy control: from attention to prevalence (elimination as a public health problem) to incidence (reducing transmission), from only passive case-reporting to providing funds for active case-finding activities to promote early detection and prevent nerve damage, renewed attention to detection and treatment of silent neuritis, treatment of reactions and prevention of further disability, upgrading skin smear services, attention to possible drug and multidrug resistance in leprosy, the importance of post-MDT chemoprophylaxis in the case of LL patients, Post-Exposure Prophylaxis (PEP) in leprosy, promoting respect for human rights, etc. LML provided a widely-read platform for important discussions on such topics.

 

Suggestions have been made to transform LML into an online Community of Practice (CoPs). Community of Practice is a vehicle for capturing knowledge to ensure public health preparedness, managing information more effectively, enabling global health professionals to work collaboratively in a virtual environment, and improving effectiveness in the face of dwindling resources. Online CoPs provide a virtual space for people who share a common interest and are working towards a shared goal.

 

Those of the editorial board who participated in such online fora were of the opinion that we should not go this direction. The fear is that  even that even with CoPs only a small percentage of those health professionals and stakeholders will be active participants in those discussions.

 

Nevertheless, we would like to appeal to our readers to take up the challenge and contribute to ongoing discussions or bring new items. Once more, LML is an open forum – we welcome all contributions – accept the challenge and be open-minded

 

Last but no least, the members of the editorial board of LML past the retirement age ages ago. We would like to appeal to a younger generation to take up the challenge and safe-guard LML for the future. LML is needed, LML makes a difference."

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/a106fb33-28aa-4b27-95d1-b9ffa6801933n%40googlegroups.com.